His primary scientific interests are in Antigen, Immunology, T cell, Immunotherapy and Chimeric antigen receptor. His Antigen research includes themes of Cytotoxic T cell and Adoptive cell transfer. His study focuses on the intersection of Immunology and fields such as Transplantation with connections in the field of Chronic myelogenous leukemia.
His T cell study integrates concerns from other disciplines, such as Graft-versus-host disease, Ex vivo, Protein kinase A and B cell. The study incorporates disciplines such as Pathology, Antibody, In vivo and Monoclonal in addition to Immunotherapy. His work deals with themes such as Cancer research and Prostate cancer, which intersect with Chimeric antigen receptor.
J. Joseph Melenhorst mainly focuses on Immunology, T cell, Chimeric antigen receptor, CD8 and Antigen. His Immunology research is multidisciplinary, incorporating elements of Internal medicine and Stem cell. His work carried out in the field of T cell brings together such families of science as Cytotoxic T cell, Lymphocyte, Oncology and B cell.
His Chimeric antigen receptor research incorporates themes from Cancer research, Cell therapy and CD19. The CD8 study combines topics in areas such as T lymphocyte, Molecular biology, Human leukocyte antigen, T-cell receptor and Transplantation. In his research on the topic of Antigen, Chronic lymphocytic leukemia is strongly related with Antibody.
J. Joseph Melenhorst spends much of his time researching Chimeric antigen receptor, Immunotherapy, Cancer research, T cell and Antigen. His Chimeric antigen receptor research is multidisciplinary, relying on both B cell, Adoptive cell transfer, CD19 and Lymphoma. Immunotherapy is a subfield of Immunology that J. Joseph Melenhorst investigates.
His research in Cancer research intersects with topics in Mesothelin, Cancer, Cell, Cell therapy and Immune system. His T cell study combines topics from a wide range of disciplines, such as Oncology, Diffuse large B-cell lymphoma, Internal medicine, Genetic enhancement and Computational biology. His Antigen research integrates issues from Tumor necrosis factor alpha, Receptor, Chimeric Antigen Receptor T-Cell Therapy and Lymph node.
His primary areas of investigation include Immunotherapy, Antigen, Chimeric antigen receptor, Cancer research and Cytokine release syndrome. His studies deal with areas such as Leukemia, Antibody and Monoclonal as well as Immunotherapy. His Antigen study frequently involves adjacent topics like T cell.
J. Joseph Melenhorst combines subjects such as Immune system, CD19, Lymphoma, Transforming growth factor and In vivo with his study of Cancer research. J. Joseph Melenhorst is investigating Cytokine release syndrome as part of his Immunology and Internal medicine and Cytokine release syndrome study. The concepts of his Immunology study are interwoven with issues in Toxicity and Epidermal growth factor receptor.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L. Maude;Noelle Frey;Pamela A. Shaw;Richard Aplenc.
The New England Journal of Medicine (2014)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter;Wei-Ting Hwang;Noelle V. Frey;Simon F. Lacey.
Science Translational Medicine (2015)
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster;Jakub Svoboda;Elise A. Chong;Sunita D. Nasta.
The New England Journal of Medicine (2017)
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Elena Sotillo;David M. Barrett;Kathryn L. Black;Asen Bagashev.
Cancer Discovery (2015)
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Donald M. O’Rourke;MacLean P. Nasrallah;Arati Desai;Jan J. Melenhorst.
Science Translational Medicine (2017)
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia
David T. Teachey;David T. Teachey;Simon F. Lacey;Pamela A. Shaw;J. Joseph Melenhorst.
Cancer Discovery (2016)
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.
Joseph A. Fraietta;Simon F. Lacey;Elena J. Orlando;Iulian Pruteanu-Malinici.
Nature Medicine (2018)
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Alfred L. Garfall;Marcela V. Maus;Wei-Ting Hwang;Simon F. Lacey.
The New England Journal of Medicine (2015)
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
Marco Ruella;David M. Barrett;Saad S. Kenderian;Olga Shestova.
Journal of Clinical Investigation (2016)
PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.
Elise A. Chong;J. Joseph Melenhorst;Simon F. Lacey;David E. Ambrose.
Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking d-index is inferred from publications deemed to belong to the considered discipline.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: